Mannino David M, Gan Wen Oi, Wurst Keele, Davis Kourtney J
Department of Preventive Medicine and Environmental Health, College of Public Health, University of Kentucky, Lexington.
Real World Evidence and Epidemiology, Research and Development, GlaxoSmithKline Collegeville, Pennsylvania.
Chronic Obstr Pulm Dis. 2017 Feb 3;4(2):87-96. doi: 10.15326/jcopdf.4.2.2016.0159.
: Although the overlap between asthma and COPD has been recognized for years this overlap has only recently been given a name, asthma-COPD overlap syndrome (ACOS), and better defined. Different definitions of the component diseases can affect prevalence and outcome measures of ACOS. We used data from the National Health and Nutrition Examination Survey (NHANES) from 2007-2012 to determine the population estimates of ACOS in U.S. adults using 2 different definitions of ACOS (ACOS1= self-reported COPD and current asthma; ACOS2 = spirometric-confirmed COPD [pre-bronchodilator FEV/FVC < 70%] and current asthma) and to describe variation in other factors, such as lung function impairment and health care utilization, by ACOS definitions. Among U.S. adults aged 20 and older, 1.6% had ACOS1, and 1.9% had ACOS2. Both case definitions were similar with regard to symptoms and impairment of lung function. ACOS1 individuals were more likely to have one or more overnight hospital stays relative to those with neither asthma nor COPD, (odds ratio [OR] 3.4, 95% confidence interval [CI] 2.5, 4.6) than ACOS2 (OR 1.6, 95% CI 0.9, 2.9). : Different definitions of ACOS in population-based studies affect both estimates of disease prevalence and outcomes related to the disease. These definitions need to be carefully considered in the design of epidemiologic studies and clinical trials.
尽管哮喘与慢性阻塞性肺疾病(COPD)之间的重叠现象已被认识多年,但这种重叠直到最近才有了一个名称,即哮喘-COPD重叠综合征(ACOS),并且得到了更明确的定义。组成疾病的不同定义会影响ACOS的患病率和结局指标。我们使用了2007 - 2012年美国国家健康与营养检查调查(NHANES)的数据,通过ACOS的两种不同定义(ACOS1 = 自我报告的COPD和当前哮喘;ACOS2 = 肺量计确诊的COPD[支气管扩张剂前FEV/FVC < 70%]和当前哮喘)来确定美国成年人中ACOS的人群估计数,并按ACOS定义描述其他因素的差异,如肺功能损害和医疗保健利用情况。在20岁及以上的美国成年人中,1.6%患有ACOS1,1.9%患有ACOS2。两种病例定义在症状和肺功能损害方面相似。与既无哮喘也无COPD的人相比,ACOS1个体更有可能有一次或多次过夜住院(优势比[OR] 3.4,95%置信区间[CI] 2.5,4.6),而ACOS2个体的这一比例为(OR 1.6,95% CI 0.9,2.9)。基于人群的研究中ACOS的不同定义会影响疾病患病率的估计以及与该疾病相关的结局。在流行病学研究和临床试验的设计中需要仔细考虑这些定义。